Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Dermatophytosis Treatment Market size was valued at USD 9.27 billion in 2024 and is likely to cross USD 17.05 billion by 2037, expanding at more than 4.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of dermatophytosis treatment is estimated at USD 9.65 billion.
The growth of the dermatophytosis treatment market can be attributed to the growing population of people with weak immune systems, and rising incidences of sedentary lifestyle among people. Along with these, increasing geriatric population contributing to the high occurrence of dermatophytosis across the globe is also expected to significantly raise the demand for the treatment in the forthcoming years. According to the World Health Organization, between 2015 to 2050, the percentage of the world’s population aged 60 years and older will nearly double from 12 percent to 22 percent. In 2050, 80% of older people will be living in low- and middle-income countries.
Upsurge in the number of hospital-acquired diseases is also predicted to expand the market in the near future. Furthermore, escalating private investments for conducting research and development activities to develop novel treatment in developed nations, and rise in healthcare funding are assessed to offer profitable opportunities for dermatophytosis treatment market growth in the imminent time.
Dermatophytosis Treatment Sector: Growth Drivers and Challenges
Growth Drivers
-
Growing Population of People with Weak Immune Systems
-
Rising Incidences of Sedentary Lifestyle Among People
Challenges
-
Availability of Alternative Treatment Options
Dermatophytosis Treatment Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.8% |
|
Base Year Market Size (2024) |
USD 9.27 billion |
|
Forecast Year Market Size (2037) |
USD 17.05 billion |
|
Regional Scope |
|
Dermatophytosis Treatment Segmentation
The dermatophytosis treatment market is segmented by drug used into imidazole, econazole, clotrimazole, miconazole, ketoconazole, terbinafine, clotrimazole, corticosteroid, terbinafine, itraconazole, griseofulvin, and others, out of which, the itraconazole segment is anticipated to hold the largest share in the global market. This can be accounted to the broad antifungal spectrum and excellent effectiveness of this drug against fungal infections. Apart from these, high usage of itraconazole capsules for treating infections of the toenails is also projected to drive the segment’s growth in the future. Additionally, on the basis of end user, the clinics segment is evaluated to grab the largest share during the forecast period owing to the growing preference of patients to get treated by medical professionals operating in a specialty clinic facility.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
Drug Used |
|
|
End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportDermatophytosis Treatment Industry - Regional Synopsis
On the basis of geographical analysis, the dermatophytosis treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the Asia Pacific industry is poised to hold largest revenue share by 2037, propelled by increasing geriatric population, and significant improvements in the healthcare facility in the region. sIn addition, rise in disposable income and literacy levels is also projected to boost the region’s market growth in the coming years. In the ASEAN region, Singapore accounts for the highest disposable income of approximately USD 30 thousand as of 2021, whereas Malaysia’s disposable income is calculated to reach a value of close to USD 5 thousand. Moreover, the dermatophytosis treatment market in North America is anticipated to acquire the largest share during the forecast period ascribing to the availability of highly developed healthcare infrastructure, favorable reimbursement policies, and growing awareness about the benefits of early diagnosis of the disease.
Companies Dominating the Dermatophytosis Treatment Landscape
- Galderma S.A.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Pfizer, Inc.
- Moberg Pharma AB
- Janssen Global Services, LLC
- Valeant Pharmaceuticals International Inc.
- Anacor Pharmaceuticals, Inc.
- NovaQuest Capital Management, L.L.C.
- Novan, Inc
- Valeant Pharmaceuticals International Inc.
Recent Developments
-
April 2021- Galderma announced the publication of phase 2b trial results demonstrating the long-lasting and rapid benefits of nemolizumab.
Author Credits: Radhika Pawar
- Report ID: 3631
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
